-
Something wrong with this record ?
Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PLpro and Mpro proteases, and nsp14 guanine N7-methyltransferase
M. Zmudzinski, W. Rut, K. Olech, J. Granda, M. Giurg, M. Burda-Grabowska, R. Kaleta, M. Zgarbova, R. Kasprzyk, L. Zhang, X. Sun, Z. Lv, D. Nayak, M. Kesik-Brodacka, SK. Olsen, J. Weber, R. Hilgenfeld, J. Jemielity, M. Drag
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
Grant support
R01 GM128731
NIGMS NIH HHS - United States
R01 GM115568
NIGMS NIH HHS - United States
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
Nature Open Access
from 2011-12-01
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Health & Medicine (ProQuest)
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
- MeSH
- Antiviral Agents pharmacology metabolism MeSH
- COVID-19 * MeSH
- Cysteine Endopeptidases metabolism MeSH
- Protease Inhibitors pharmacology MeSH
- Humans MeSH
- Methyltransferases MeSH
- Peptide Hydrolases MeSH
- SARS-CoV-2 * metabolism MeSH
- Molecular Docking Simulation MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, N.I.H., Extramural MeSH
Proteases encoded by SARS-CoV-2 constitute a promising target for new therapies against COVID-19. SARS-CoV-2 main protease (Mpro, 3CLpro) and papain-like protease (PLpro) are responsible for viral polyprotein cleavage-a process crucial for viral survival and replication. Recently it was shown that 2-phenylbenzisoselenazol-3(2H)-one (ebselen), an organoselenium anti-inflammatory small-molecule drug, is a potent, covalent inhibitor of both the proteases and its potency was evaluated in enzymatic and antiviral assays. In this study, we screened a collection of 34 ebselen and ebselen diselenide derivatives for SARS-CoV-2 PLpro and Mpro inhibitors. Our studies revealed that ebselen derivatives are potent inhibitors of both the proteases. We identified three PLpro and four Mpro inhibitors superior to ebselen. Independently, ebselen was shown to inhibit the N7-methyltransferase activity of SARS-CoV-2 nsp14 protein involved in viral RNA cap modification. Hence, selected compounds were also evaluated as nsp14 inhibitors. In the second part of our work, we employed 11 ebselen analogues-bis(2-carbamoylaryl)phenyl diselenides-in biological assays to evaluate their anti-SARS-CoV-2 activity in Vero E6 cells. We present their antiviral and cytoprotective activity and also low cytotoxicity. Our work shows that ebselen, its derivatives, and diselenide analogues constitute a promising platform for development of new antivirals targeting the SARS-CoV-2 virus.
Centre of New Technologies University of Warsaw Banacha 2C 02 097 Warsaw Poland
Institute of Molecular Medicine University of Lübeck Ratzeburger Allee 160 23562 Lübeck Germany
National Medicines Institute Ul Chełmska 30 34 00 725 Warsaw Poland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011102
- 003
- CZ-PrNML
- 005
- 20230801132816.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-023-35907-w $2 doi
- 035 __
- $a (PubMed)37280236
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Zmudzinski, Mikolaj $u Department of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370, Wroclaw, Poland. mikolaj.zmudzinski@pwr.edu.pl
- 245 10
- $a Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PLpro and Mpro proteases, and nsp14 guanine N7-methyltransferase / $c M. Zmudzinski, W. Rut, K. Olech, J. Granda, M. Giurg, M. Burda-Grabowska, R. Kaleta, M. Zgarbova, R. Kasprzyk, L. Zhang, X. Sun, Z. Lv, D. Nayak, M. Kesik-Brodacka, SK. Olsen, J. Weber, R. Hilgenfeld, J. Jemielity, M. Drag
- 520 9_
- $a Proteases encoded by SARS-CoV-2 constitute a promising target for new therapies against COVID-19. SARS-CoV-2 main protease (Mpro, 3CLpro) and papain-like protease (PLpro) are responsible for viral polyprotein cleavage-a process crucial for viral survival and replication. Recently it was shown that 2-phenylbenzisoselenazol-3(2H)-one (ebselen), an organoselenium anti-inflammatory small-molecule drug, is a potent, covalent inhibitor of both the proteases and its potency was evaluated in enzymatic and antiviral assays. In this study, we screened a collection of 34 ebselen and ebselen diselenide derivatives for SARS-CoV-2 PLpro and Mpro inhibitors. Our studies revealed that ebselen derivatives are potent inhibitors of both the proteases. We identified three PLpro and four Mpro inhibitors superior to ebselen. Independently, ebselen was shown to inhibit the N7-methyltransferase activity of SARS-CoV-2 nsp14 protein involved in viral RNA cap modification. Hence, selected compounds were also evaluated as nsp14 inhibitors. In the second part of our work, we employed 11 ebselen analogues-bis(2-carbamoylaryl)phenyl diselenides-in biological assays to evaluate their anti-SARS-CoV-2 activity in Vero E6 cells. We present their antiviral and cytoprotective activity and also low cytotoxicity. Our work shows that ebselen, its derivatives, and diselenide analogues constitute a promising platform for development of new antivirals targeting the SARS-CoV-2 virus.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a SARS-CoV-2 $x metabolismus $7 D000086402
- 650 12
- $a COVID-19 $7 D000086382
- 650 _2
- $a methyltransferasy $7 D008780
- 650 _2
- $a proteasy $7 D010447
- 650 _2
- $a antivirové látky $x farmakologie $x metabolismus $7 D000998
- 650 _2
- $a cysteinové endopeptidasy $x metabolismus $7 D003546
- 650 _2
- $a inhibitory proteas $x farmakologie $7 D011480
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 700 1_
- $a Rut, Wioletta $u Department of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370, Wroclaw, Poland
- 700 1_
- $a Olech, Kamila $u Department of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370, Wroclaw, Poland
- 700 1_
- $a Granda, Jarosław $u Department of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370, Wroclaw, Poland
- 700 1_
- $a Giurg, Mirosław $u Department of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370, Wroclaw, Poland
- 700 1_
- $a Burda-Grabowska, Małgorzata $u Department of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370, Wroclaw, Poland
- 700 1_
- $a Kaleta, Rafał $u Department of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370, Wroclaw, Poland
- 700 1_
- $a Zgarbova, Michala $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo Nám. 2, 16610, Prague, Czech Republic
- 700 1_
- $a Kasprzyk, Renata $u Centre of New Technologies, University of Warsaw, Banacha 2C, 02-097, Warsaw, Poland $u College of Inter-Faculty Individual Studies in Mathematics and Natural Sciences, University of Warsaw, Banacha 2C, 02-097, Warsaw, Poland
- 700 1_
- $a Zhang, Linlin $u Institute of Molecular Medicine, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany
- 700 1_
- $a Sun, Xinyuanyuan $u Institute of Molecular Medicine, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany
- 700 1_
- $a Lv, Zongyang $u Department of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA
- 700 1_
- $a Nayak, Digant $u Department of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA
- 700 1_
- $a Kesik-Brodacka, Malgorzata $u National Medicines Institute, Ul. Chełmska 30/34, 00-725, Warsaw, Poland
- 700 1_
- $a Olsen, Shaun K $u Department of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA
- 700 1_
- $a Weber, Jan $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo Nám. 2, 16610, Prague, Czech Republic
- 700 1_
- $a Hilgenfeld, Rolf $u Institute of Molecular Medicine, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany $u German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems Site, University of Lübeck, 23562, Lübeck, Germany
- 700 1_
- $a Jemielity, Jacek $u Centre of New Technologies, University of Warsaw, Banacha 2C, 02-097, Warsaw, Poland
- 700 1_
- $a Drag, Marcin $u Department of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370, Wroclaw, Poland. marcin.drag@pwr.edu.pl
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 13, č. 1 (2023), s. 9161
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37280236 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132813 $b ABA008
- 999 __
- $a ok $b bmc $g 1963479 $s 1197367
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 13 $c 1 $d 9161 $e 20230606 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- GRA __
- $a R01 GM128731 $p NIGMS NIH HHS $2 United States
- GRA __
- $a R01 GM115568 $p NIGMS NIH HHS $2 United States
- LZP __
- $a Pubmed-20230718